Form 4: Phio Pharmaceuticals CEO Reports Stock Transaction
Insider Transaction (Form 4)
Robert J Bitterman, Chairman, Pres. & CEO and a Director of Phio Pharmaceuticals Corp., reported a transaction in 68,550 shares of common stock on September 11, 2026.
Summary
- Tax/exercise-price withholding: disposed of 68,550 Common Stock, $.0001 par value at $1.03 ($70,606) on September 11, 2026; holds 362,871 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Robert J Bitterman — Director, Officer (Chairman, Pres. & CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-11 | Tax/exercise-price withholding | Common Stock, $.0001 par value | 68,550 | $1 | $70.6K | 362,871 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-11 | Tax/exercise-price withholding (68,550 shares) |
Keywords
insider transaction, Form 4, PHIO, Phio Pharmaceuticals Corp., neutral, Robert J Bitterman
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.